CompletedPhase 2NCT02636868

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

Studying Infant acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Windtree Therapeutics
Principal Investigator
Steven Simonson, MD
Windtree Therapeutics
Intervention
Lucinactant delivered via investigational delivery device(drug)
Enrollment
221 enrolled
Eligibility
All sexes
Timeline
20152019

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02636868 on ClinicalTrials.gov

Other trials for Infant acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Infant acute respiratory distress syndrome

← Back to all trials